Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 2.595
1.
  • Lack of association between... Lack of association between human plasma oxytocin and interpersonal trust in a Prisoner's Dilemma paradigm
    Christensen, James C; Shiyanov, Pavel A; Estepp, Justin R ... PloS one, 12/2014, Letnik: 9, Številka: 12
    Journal Article
    Recenzirano
    Odprti dostop

    Expanding interest in oxytocin, particularly the role of endogenous oxytocin in human social behavior, has created a pressing need for replication of results and verification of assay methods. In ...
Celotno besedilo
Dostopno za: DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK

PDF
2.
  • Adagrasib in Non–Small-Cell... Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
    Jänne, Pasi A.; Riely, Gregory J.; Gadgeel, Shirish M. ... The New England journal of medicine, 07/2022, Letnik: 387, Številka: 2
    Journal Article
    Recenzirano

    Adagrasib produced responses in 43% of previously treated patients with non–small-cell lung cancer containing a KRAS G12C mutation, with median overall survival of 12.6 months. Regressions of stable ...
Celotno besedilo
Dostopno za: CMK, UL
3.
  • Adagrasib with or without C... Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
    Yaeger, Rona; Weiss, Jared; Pelster, Meredith S. ... The New England journal of medicine, 01/2023, Letnik: 388, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with cetuximab, an epidermal growth factor ...
Celotno besedilo
Dostopno za: CMK, UL
4.
  • Efficacy of a Small-Molecul... Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
    Kemp, Samantha B; Cheng, Noah; Markosyan, Nune ... Cancer discovery, 02/2023, Letnik: 13, Številka: 2
    Journal Article
    Odprti dostop

    Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the ...
Celotno besedilo
Dostopno za: UL
5.
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK
6.
  • Enhanced efficacy of sitrav... Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
    Dolan, Melissa; Mastri, Michalis; Tracz, Amanda ... PloS one, 08/2019, Letnik: 14, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    Tyrosine kinase inhibitors (TKIs) that primarily target angiogenesis are approved to treat several cancers in the metastatic setting; however, resistance is common. Sequential treatment or ...
Celotno besedilo
Dostopno za: DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK

PDF
7.
  • Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Sequist, Lecia V; Waltman, Belinda A; Dias-Santagata, Dora ... Science translational medicine, 2011-Mar-23, Letnik: 3, Številka: 75
    Journal Article
    Recenzirano
    Odprti dostop

    Lung cancers harboring mutations in the epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitors, but drug resistance invariably emerges. To elucidate mechanisms of acquired ...
Celotno besedilo

PDF
8.
  • The neuroblastoma-associate... The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
    Sasaki, Takaaki; Okuda, Katsuhiro; Zheng, Wei ... Cancer research (Chicago, Ill.), 12/2010, Letnik: 70, Številka: 24
    Journal Article
    Recenzirano
    Odprti dostop

    The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance. Here we ...
Celotno besedilo
Dostopno za: CMK, UL

PDF
9.
  • c-Met as a target for human... c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
    Christensen, James G.; Burrows, Jon; Salgia, Ravi Cancer letters, 07/2005, Letnik: 225, Številka: 1
    Journal Article
    Recenzirano

    Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
10.
  • MET Amplification Identifie... MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
    LENNERZ, Jochen K; KWAK, Eunice L; SALGIA, Ravi ... Journal of clinical oncology, 12/2011, Letnik: 29, Številka: 36
    Journal Article
    Recenzirano
    Odprti dostop

    Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow-up and reported the clinical ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
1 2 3 4 5
zadetkov: 2.595

Nalaganje filtrov